Keywords: prostatic neoplasms; biological markers; risk assessment; molecular diagnostic techniques; ADT; androgen deprivation therapy; AS; active surveillance; Columbia; New York-Presbyterian Hospital, Columbia University; DVU; Delaware Valley Urology, LLC; EBRT;